Briefs · Frontier Science
Pfizer bought a diet, not a drug
Pfizer missed the first obesity gold rush. It has now bought its way into the second one.
On 22 September, Pfizer agreed to acquire Metsera, a clinical-stage developer of next-generation obesity and cardiometabolic medicines, for $47.50 a share in cash — an enterprise value of about $4.9 billion — plus a contingent value right worth up to $22.50 a share if three clinical and regulatory milestones are hit. The deal was expected to close in the fourth quarter of 2025.
What Pfizer is buying is not a drug, but rather a pipeline: four clinical-stage incretin and amylin programmes, including the GLP-1 receptor agonist MET-097i and the long-acting amylin analogue MET-233i, and their combination. Metsera’s candidates are designed to be taken less often, with fewer side effects — the two complaints that keep patients off today’s weight-loss drugs.
Officially, this is a bolt-on acquisition. Unofficially, it is an admission: the obesity market is the biggest drug market of the decade, and Pfizer was standing outside it.
Conclusion: Pfizer is not late to obesity, but rather paying the late fee — a plump price for a second chance.
Summary in our own words. The original belongs to its publisher.